Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
SAN DIEGO, Nov 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
Piper Jaffray 20th Annual Health Care Conference on December 3, 2008 at 2:30
p.m. Eastern Time (11:30 a.m. Pacific Time) at the New York Palace Hotel in
New York City. Jack Lief, Arena's President and Chief Executive Officer, is
scheduled to provide an overview of the company, including its clinical
development and discovery programs.
A live audio webcast of the presentation will be available under the
investor relations section of Arena's website at http://www.arenapharm.com. A
replay of the presentation will be available for 30 days following the event.
Please connect to Arena's website several minutes prior to the start of the
webcast to ensure adequate time for any software download that may be
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory and
metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being
investigated in a Phase 3 clinical trial program for the treatment of obesity.
Arena's broad pipeline of novel compounds target G protein-coupled receptors,
an important class of validated drug targets, and includes compounds being
evaluated independently and with partners, including Merck & Co., Inc. and
Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, internal and partnered
programs, and ability to develop compounds and commercialize drugs. For such
statements, Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not limited
to, clinical trials and studies may not proceed at the time or in the manner
Arena expects or at all, the results of clinical trials or preclinical studies
may not be predictive of future results, Arena's ability to receive regulatory
approval for its drug candidates, Arena's ability to partner lorcaserin,
APD125, APD791 or other of its compounds or programs, the timing, success and
cost of Arena's research, out-licensing endeavors and clinical trials, Arena's
ability to obtain additional financing, Arena's ability to obtain and defend
its patents and the timing and receipt of payments and fees, if any, from
Arena's collaborators. Additional factors that could cause actual results to
differ materially from those stated or implied by Arena's forward-looking
statements are disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's judgment as of
the time of this release. Arena disclaims any intent or obligation to update
these forward-looking statements, other than as may be required under
Contacts: Jack Lief Mary Claire Duch
President and CEO WeissComm Partners
David Walsey 212.301.7228
Director, Corporate Communications
Arena Pharmaceuticals, Inc.
858.453.7200, ext. 1682
SOURCE Arena Pharmaceuticals, Inc.
Copyright (C) 2008 PR Newswire. All rights reserved